Table 3 Survival rates (95% confidence intervals) of immunosuppressive/antiproliferative and vasoactive agents in 181 patients with Systemic sclerosis

Immunosuppressives

Methotrexate *

Cyclophosphamide **

Mycophenolate***

Azathioprine

 6 months

0.91 (0.84–0.95)

0.76 (0.60–0.86)

0.95 (0.70–0.98)

0.88 (0.62–0.97)

 12 months

0.84 (0.75–0.90)

0.59 (0.42–0.72)

0.74 (0.48–0.88)

0.78 (0.51–0.91)

 24 months

0.75 (0.66–0.83)

0.43 (0.27–0.58)

0.63 (0.40–0.80)

0.60 (0.34–0.78)

 36 months

0.72 (0.62–0.80)

0.26 (0.13–0.40)

0.53 (0.32–0.74)

0.47 (0.23–0.67)

 48 months

0.65 (0.54–0.74)

0.16 (0.06–0.30)

0.40 (0.20–0.61)

0.33 (0.12–0.54)

Vasoactives

Endotelin-receptor antagonists⁺

Sildenafil⁺⁺

Calcium channel blockers

–

 6 months

0.92 (0.84–0.96)

0.93 (0.69–0.99)

0.99 (0.93–0.99)

–

 12 months

0.88 (0.78–0.94)

0.8 (0.52–0.93)

0.97 (0.91–0.99)

–

 24 months

0.86 (0.76–0.92)

0.8 (0.52–0.93)

0.91 (0.85–0.96)

–

 36 months

0.84 (0.73–0.91)

0.70 (0.41–0.88)

0.87 (0.78–0.92)

–

 48 months

0.79 (0.66–0.88)

0.70 (0.41–0.88)

0.83 (0.74–0.89)

–